Towards Healthcare
Liquid Biopsy Market Size Leads by 14.5% CAGR till 2034

Liquid Biopsy Market Trends & Innovations in Cancer Detection

According to market projections, the liquid biopsy sector is expected to grow from USD 6.18 billion in 2024 to USD 23.94 billion by 2034, reflecting a CAGR of 14.5%, driven by the need for non-invasive cancer diagnostics. It enables real-time monitoring, early detection, and personalized treatment. Advances in NGS, ctDNA analysis, and AI are enhancing accuracy. The technology is expanding beyond oncology into neurology, infections, and transplants.

Content

Executive Summary

  • Overview of Liquid Biopsy Market
  • Key Market Trends
  • Market Forecast and Opportunities

Introduction

  • Definition and Scope
  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
    • Challenges

Market Overview

  • Market Size and Growth Analysis
  • Historical Market Trends
  • Competitive Landscape

Market Segmentation

  • By Technology
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • Fluorescence In Situ Hybridization (FISH)
    • Other Technologies
  • By Usage
    • Research Use Only (RUO)
    • Clinical Use
  • By Types of Sample
    • Blood
    • Urine
    • Saliva
    • Cerebrospinal Fluid
  • By Circulating Biomarker
    • Circulating Tumor Cells (CTCs)
    • Cell-free DNA (cfDNA)
    • Circulating Cell-Free RNA (ccfRNA)
    • Exosomes and Extracellular Vesicles
    • Others
  • By Products
    • Tests/Services
    • Kits and Consumables
    • Instruments
  • By Indication Type
    • Lung Cancer
    • Breast Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Melanoma
    • Other Cancers
    • Non-Oncology Disorders
  • By Clinical Application
    • Treatment Monitoring
    • Prognosis and Recurrence Monitoring
    • Treatment Selection
    • Diagnosis and Screening

Regional Analysis

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Cross Segmentations

By Technology

  • NGS (Next-Generation Sequencing)
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • PCR (Polymerase Chain Reaction)
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • FISH (Fluorescence In Situ Hybridization)
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Other Technologies
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)

By Usage

  • RUO (Research Use Only)
    • Technology: NGS, PCR, FISH, Other
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Clinical
    • Technology: NGS, PCR, FISH, Other
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)

By Types of Sample

  • Blood
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Urine
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Saliva
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Cerebrospinal Fluid
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)

By Circulating Biomarker

  • Circulating Tumor Cells
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Cell-free DNA
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Circulating Cell-Free RNA
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Exosomes and Extracellular Vesicles
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Others
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)

By Products

  • Test/Services
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Kits and Consumables
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Instruments
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)

By Indication Type

  • Lung Cancer
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Breast Cancer
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Prostate Cancer
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Colorectal Cancer
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Melanoma
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Other Cancers
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Non-Oncology Disorders
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)

By Clinical Application

  • Treatment Monitoring
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Prognosis and Recurrence Monitoring
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Treatment Selection
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)
  • Diagnosis and Screening
    • Technology: NGS, PCR, FISH, Other
    • Usage: Clinical, RUO
    • Types of Sample: Blood, Urine, Saliva, Cerebrospinal Fluid
    • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
    • Products: Test/Services, Kits and Consumables, Instruments
    • Indication Type: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders
    • Geography: North America (U.S., Canada), Europe (U.K., Germany, France), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Philippines), Latin America (Brazil, Rest of Latin America), Middle East & Africa (MEA) (GCC, North Africa, South Africa, Rest of the Middle East & Africa)

By Geography

  • North America
    • U.S.
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • Canada
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
  • Europe
    • U.K.
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • Germany
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • France
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
  • Asia-Pacific
    • China
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • India
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • Japan
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • South Korea
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • Malaysia
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • Philippines
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
  • Latin America
    • Brazil
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • Rest of Latin America
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
  • Middle East & Africa (MEA)
    • GCC
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • North Africa
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • South Africa
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments
    • Rest of the Middle East & Africa
      • Circulating Biomarker: Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles
      • Technology: NGS, PCR, FISH, Other
      • Clinical Application: Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening
      • Sample Type: Blood, Urine, Saliva, Cerebrospinal Fluid
      • Products: Test/Services, Kits and Consumables, Instruments

Go-to-Market Strategies (Selective Region)

Product Differentiation

  • Recommendations:
    • Focus on advancing technologies such as Next-Generation Sequencing (NGS) and innovative PCR methods.
    • Develop customized solutions for various clinical applications and sample types to meet specific market needs.
  • Objectives:
    • Establish a leadership position in technology innovation and product differentiation.
    • Enhance market appeal by offering tailored solutions that address diverse clinical requirements.
  • Challenges:
    • Keeping pace with rapid technological advancements and ensuring continuous innovation.
    • Balancing customization with cost-efficiency to meet diverse market demands.

Strategic Partnerships and Collaborations

  • Recommendations:
    • Form partnerships with academic and research institutions for technology advancement.
    • Collaborate with healthcare providers and clinical labs to integrate liquid biopsy solutions into clinical workflows.
  • Objectives:
    • Leverage external expertise and resources to enhance product development and market reach.
    • Build strong relationships with key stakeholders to drive adoption and integration.
  • Challenges:
    • Navigating complex partnership negotiations and aligning goals with external partners.
    • Ensuring effective integration of solutions within existing clinical practices.

Market Penetration

  • Recommendations:
    • Implement targeted marketing campaigns to reach healthcare professionals and researchers.
    • Expand regional presence in emerging markets with growing healthcare infrastructure.
  • Objectives:
    • Increase market visibility and adoption through focused marketing efforts.
    • Capture market share in new and underserved regions.
  • Challenges:
    • Overcoming market entry barriers in new regions.
    • Effectively communicating the benefits of liquid biopsy solutions to diverse audiences.

Regulatory and Reimbursement Strategy

  • Recommendations:
    • Ensure compliance with regional regulatory requirements and obtain necessary certifications.
    • Work with insurance companies and healthcare providers to establish reimbursement codes.
  • Objectives:
    • Build credibility and trust through regulatory compliance and certification.
    • Facilitate broader adoption by ensuring reimbursement coverage for liquid biopsy tests.
  • Challenges:
    • Navigating complex regulatory processes and achieving timely approvals.
    • Securing reimbursement agreements and addressing potential coverage limitations.

Educational and Training Programs

  • Recommendations:
    • Offer educational programs and workshops for healthcare professionals on liquid biopsy technologies.
    • Conduct awareness campaigns to highlight the benefits and applications of liquid biopsy.
  • Objectives:
    • Enhance user knowledge and confidence in using liquid biopsy solutions.
    • Increase market awareness and drive adoption through educational initiatives.
  • Challenges:
    • Developing effective training materials and programs that resonate with target audiences.
    • Ensuring broad participation and engagement in educational activities.

Sales and Distribution Channels

  • Recommendations:
    • Build a dedicated sales team with expertise in oncology and diagnostics.
    • Collaborate with established distributors to expand market reach.
  • Objectives:
    • Drive direct sales and foster relationships with key accounts.
    • Enhance distribution efficiency and market coverage through partnerships.
  • Challenges:
    • Managing a sales team and distributor relationships effectively.
    • Ensuring consistent product availability and support across various regions.

Customer Support and Service

  • Recommendations:
    • Provide robust customer support, including technical assistance and troubleshooting.
    • Implement a feedback system to gather insights and refine products and services.
  • Objectives:
    • Enhance user satisfaction and loyalty through comprehensive support.
    • Continuously improve offerings based on customer feedback.
  • Challenges:
    • Maintaining high levels of support quality and responsiveness.
    • Effectively integrating feedback into product development and service enhancements.

Market Intelligence and Adaptation

  • Recommendations:
    • Continuously monitor competitor activities and market trends.
    • Utilize market research and data analytics for strategic decision-making.
  • Objectives:
    • Stay ahead of market trends and maintain a competitive edge.
    • Make informed decisions to drive growth and adapt to market changes.
  • Challenges:
    • Keeping up with rapidly changing market dynamics and competitor strategies.
    • Effectively analyzing and applying market data to drive strategic initiatives.

Integration of AI in the Liquid Biopsy Market

  • Enhanced Data Analysis and Interpretation
    • Recommendations:
      • Implement AI algorithms to analyze complex biomarker data from liquid biopsies.
    • Objectives:
      • Increase diagnostic precision and reduce human error.
      • Accelerate data processing for timely insights.
    • Challenges:
      • Developing AI models for diverse, high-dimensional data.
      • Ensuring AI reliability in clinical settings.
  • Predictive Analytics for Patient Outcomes
    • Recommendations:
      • Utilize AI for predictive modeling to forecast patient responses to treatments.
    • Objectives:
      • Enhance personalized medicine by predicting treatment efficacy.
      • Support data-driven treatment decisions.
    • Challenges:
      • Integrating AI with clinical workflows and electronic health records.
      • Addressing ethical and regulatory concerns.
  • Automated Sample Processing and Quality Control
    • Recommendations:
      • Deploy AI-driven automation for sample processing and quality control.
    • Objectives:
      • Improve efficiency and consistency in sample handling.
      • Reduce manual labor and potential for contamination.
    • Challenges:
      • Ensuring accuracy and reliability of automated systems.
      • Integrating automation with existing laboratory practices.
  • AI-Powered Biomarker Discovery
    • Recommendations:
      • Apply AI to identify new biomarkers and analyze their relevance.
    • Objectives:
      • Accelerate discovery of novel biomarkers for early detection.
      • Enhance applications of liquid biopsy.
    • Challenges:
      • Managing data volumes and ensuring validity of AI-discovered biomarkers.
      • Translating research discoveries to clinical applications.
  • Enhancing Diagnostic and Screening Capabilities
    • Recommendations:
      • Leverage AI to develop advanced diagnostic tools for liquid biopsy.
    • Objectives:
      • Improve detection of early-stage cancers and conditions.
      • Provide reliable diagnostic tools for screening and monitoring.
    • Challenges:
      • Validating AI tools through clinical trials and regulatory processes.
      • Ensuring user acceptance and clinical integration.
  • AI-Driven Personalized Treatment Recommendations
    • Recommendations:
      • Use AI to generate personalized treatment recommendations from liquid biopsy results.
    • Objectives:
      • Provide tailored therapy options for individual patients.
      • Design more effective and personalized treatment plans.
    • Challenges:
      • Integrating AI recommendations with clinical expertise and patient preferences.
      • Addressing transparency and explainability of AI recommendations.
  • Real-Time Monitoring and Feedback
    • Recommendations:
      • Implement AI systems for real-time monitoring of patient responses.
    • Objectives:
      • Provide continuous insights into treatment effectiveness and disease progression.
      • Enable dynamic adjustments to treatment plans.
    • Challenges:
      • Ensuring accuracy and timeliness of real-time data analysis.
      • Managing integration with existing treatment protocols.

Production and Consumption Data

  • Introduction
    • Overview of Production and Consumption in Liquid Biopsy Market
    • Key Definitions and Terminology
  • Global Production Data
    • Production Volume and Value
      • Total Production Volume (Metric Tons/Units)
      • Total Production Value (USD Million)
    • Production by Region
      • North America
      • Europe
      • Asia-Pacific
      • Latin America
      • Middle East & Africa (MEA)
    • Key Producers and Market Share
      • Leading Companies and Their Production Capacities
      • Market Share Analysis of Major Producers
  • Global Consumption Data
    • Consumption Volume and Value
      • Total Consumption Volume (Metric Tons/Units)
      • Total Consumption Value (USD Million)
    • Consumption by Region
      • North America
      • Europe
      • Asia-Pacific
      • Latin America
      • Middle East & Africa (MEA)
    • End-User Applications and Demand
      • Clinical Diagnostics
      • Research and Development
      • Other Applications
  • Production vs. Consumption Analysis
    • Production vs. Consumption Trends
      • Historical Trends and Current Data
      • Supply-Demand Imbalance Analysis
    • Impact of Production and Consumption on Market Dynamics
      • Pricing Trends
      • Market Growth and Opportunities
  • Regional Insights
    • Regional Production Insights
      • North America: Production Trends and Key Players
      • Europe: Production Trends and Key Players
      • Asia-Pacific: Production Trends and Key Players
      • Latin America: Production Trends and Key Players
      • Middle East & Africa (MEA): Production Trends and Key Players
    • Regional Consumption Insights
      • North America: Consumption Trends and Key End-Users
      • Europe: Consumption Trends and Key End-Users
      • Asia-Pacific: Consumption Trends and Key End-Users
      • Latin America: Consumption Trends and Key End-Users
      • Middle East & Africa (MEA): Consumption Trends and Key End-Users
  • Market Forecast
    • Production Forecast
      • Expected Production Growth and Trends
    • Consumption Forecast
      • Expected Consumption Growth and Trends
    • Future Market Dynamics
      • Potential Changes in Production and Consumption Patterns

Competitive Landscape

  • Company Profiles
    • Bio-Rad Laboratories
    • Biocept Inc.
    • Guardant Health
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Laboratory Corporation of America Holdings
    • MDxHealth SA
    • QIAGEN N.V
    • Thermo Fisher Scientific Inc.
  • Market Share Analysis
  • Recent Developments and Innovations
  • Strategic Initiatives

Market Opportunities and Trends

  • Emerging Trends
  • Growth Opportunities
  • Strategic Recommendations

Conclusion

  • Summary of Key Findings
  • Future Outlook

Appendices

  • Research Methodology
  • List of Abbreviations
  • Glossary of Terms
  • References
  • Insight Code: 5031
  • No. of Pages: 150
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The fastest-growing technology in the liquid biopsy market is Next-Generation Sequencing (NGS).

Liquid biopsy is commonly used for the diagnosis and monitoring of lung, breast, colorectal, and prostate cancer.

The liquid biopsy market is expected to continue to grow due to ongoing technological advancements, increasing adoption of personalized medicine, and the need for non-invasive diagnostic techniques.
Any Questions